[go: up one dir, main page]

WO2001052828A3 - Glutamine prevention of delayed-onset irinotecan-induced diarrhea - Google Patents

Glutamine prevention of delayed-onset irinotecan-induced diarrhea Download PDF

Info

Publication number
WO2001052828A3
WO2001052828A3 PCT/US2001/001270 US0101270W WO0152828A3 WO 2001052828 A3 WO2001052828 A3 WO 2001052828A3 US 0101270 W US0101270 W US 0101270W WO 0152828 A3 WO0152828 A3 WO 0152828A3
Authority
WO
WIPO (PCT)
Prior art keywords
irinotecan
glutamine
onset
delayed
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/001270
Other languages
French (fr)
Other versions
WO2001052828A2 (en
Inventor
Diane Savarese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Massachusetts Amherst
Original Assignee
University of Massachusetts Amherst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Massachusetts Amherst filed Critical University of Massachusetts Amherst
Priority to AU2001229478A priority Critical patent/AU2001229478A1/en
Publication of WO2001052828A2 publication Critical patent/WO2001052828A2/en
Publication of WO2001052828A3 publication Critical patent/WO2001052828A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Methods and compositions for inhibiting late-onset, irinotecan-induced diarrhea are disclosed. The methods include administering effective amounts of glutamine in association with irinotecan. Examples of the invention are disclosed in which oral glutamine was effective to inhibit diarrhea when administered at a rate of three 10-gram doses per day for two or three days after administration of irinotecan.
PCT/US2001/001270 2000-01-18 2001-01-12 Glutamine prevention of delayed-onset irinotecan-induced diarrhea Ceased WO2001052828A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001229478A AU2001229478A1 (en) 2000-01-18 2001-01-12 Glutamine prevention of delayed-onset irinotecan-induced diarrhea

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48496200A 2000-01-18 2000-01-18
US09/484,962 2000-01-18

Publications (2)

Publication Number Publication Date
WO2001052828A2 WO2001052828A2 (en) 2001-07-26
WO2001052828A3 true WO2001052828A3 (en) 2002-04-18

Family

ID=23926357

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/001270 Ceased WO2001052828A2 (en) 2000-01-18 2001-01-12 Glutamine prevention of delayed-onset irinotecan-induced diarrhea

Country Status (4)

Country Link
AU (1) AU2001229478A1 (en)
CO (1) CO5280204A1 (en)
PE (1) PE20011042A1 (en)
WO (1) WO2001052828A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2295429A1 (en) * 2000-01-06 2001-07-06 Michael Michael Treatment or prevention of diarrhea
WO2004103371A1 (en) * 2003-05-21 2004-12-02 Pharmacia & Upjohn Company Llc Use of cftr inhibitors for the treatment of chemotherapy-induced diarrhea

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002546A1 (en) * 1994-07-20 1996-02-01 Research Triangle Institute Water-soluble esters of camptothecin compounds
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
WO1996002546A1 (en) * 1994-07-20 1996-02-01 Research Triangle Institute Water-soluble esters of camptothecin compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D.SAVARESE E.A.: "Glutamine for irinotecan diarrhea", JOURNAL OF CLINICAL ONCOLOGY, vol. 18, no. 2, 2000, pages 450 - 451, XP001052855 *

Also Published As

Publication number Publication date
AU2001229478A1 (en) 2001-07-31
PE20011042A1 (en) 2001-09-26
WO2001052828A2 (en) 2001-07-26
CO5280204A1 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
WO2001087306A8 (en) Compositions and methods for the treatment of colorectal cancer
WO2001087307A3 (en) Compositions and methods for the treatment of cancer
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2002070438A3 (en) Compositions for delivering bisphosphonates
CA2417727A1 (en) Fentanyl composition for nasal administration
GEP20022851B (en) Flash-Melt Oral Dosage Formulation
WO2005032474A3 (en) Pharmaceutical compositions for prevention of overdose or abuse
WO2004113335A3 (en) Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
WO2002045571A3 (en) Fast dissolving tablet
CA2427227A1 (en) Lactam compound
NO2008007I2 (en)
WO2003018004A3 (en) Analgetic pyrroline derivatives
HK1040945A1 (en) Composition comprising a tramadol material and a selective cox-2 inhibitor drug
WO2004087115A3 (en) Combination compositions of camptothecins and fluoropyrimidines
WO2004105737A3 (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
GEP20043383B (en) Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds
WO2002004421A3 (en) Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
HRP20161197T1 (en) 24-norudca for treating autoimmune hepatitis
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
WO2002011724A3 (en) Neuroprotective 2-pyridinamine compositions and related methods
EP1285660A4 (en) Zinc-supplementary compositions for oral administration
WO2002012198A3 (en) 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
WO2005112967A3 (en) Anticancer activity of chios mastic gum

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP